Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firibastat for Difficult-to-treat/Resistant Hypertension (Phase 3)
2021-001404-14Phase 3Terminated
- Sponsor
- Quantum Genomics
- Start
- Jun 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Firibastat arm with Placebo then firibastat arm (2 arms). Primary endpoint: Change from baseline in systolic automated office blood pressure (AOBP) at Week 12. Started Jun 2021; status: terminated.
02
Drugs
firibastat
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2021-001404-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001404-14.